- ImmunityBio, Inc. (IBRX, Financial) reported a 129% increase in net product revenue for Q1 2025.
- ANKTIVA® unit sales volume grew 150% compared to Q4 2024.
- The company completed a $75 million equity financing to support ongoing operations.
ImmunityBio, Inc. (IBRX), a leading immunotherapy company, announced a substantial rise in its financial performance for Q1 2025, following the approval of a permanent J-code (J9028) in January 2025. The company recorded a net product revenue of approximately $16.5 million for the first quarter ended March 31, 2025, a significant 129% increase from $7.2 million in Q4 2024.
Driving this impressive financial outcome was the robust growth in ANKTIVA® unit sales, which surged by 150% over the previous quarter. Notably, March 2025 alone saw a 69% increase in unit sales over February, underpinning a strong sales momentum.
ImmunityBio continues to make strides in addressing the Bacillus Calmette-Guérin (BCG) shortage by registering nearly 200 urology practices in its recombinant BCG (rBCG) Expanded Access Program (EAP). This initiative aims to expand the market reach for ANKTIVA and provide crucial access to treatment for NMIBC carcinoma in situ (CIS) patients.
The company also reported a notable decrease in research and development expenses, with costs falling by $5.1 million to $48.2 million in Q1 2025 compared to the same period in the previous year. Similarly, selling, general, and administrative expenses were reduced by $9.2 million, totaling $32.7 million for the quarter, contributing to a narrower net loss of $129.6 million compared to $134.1 million in Q1 2024.
ImmunityBio strengthened its financial position further by completing a $75 million equity financing in April 2025, boosting its cash, cash equivalents, and marketable securities to $136.4 million as of March 31, 2025.
